| 1 |
NCT02169830 |
Recruiting |
Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine |
|
- Drug: nortriptyline
- Drug: Topiramate
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- evaluate the comparative effectiveness of migraine diet, nortriptyline and topiramate
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02169830 |
24482_ Vest_Migraine |
|
June 2014 |
July 2018 |
September 2018 |
June 23, 2014 |
October 25, 2017 |
|
- Saint Louis University
Saint Louis, Missouri, United States
|
|
| 2 |
NCT03015753 |
Recruiting |
The Efficacy of Tai Chi Training for the Prophylaxis of Migraine in Chinese Women |
|
- Behavioral: Tai Chi training
- Other: Waiting list control group
|
Interventional
|
Not Applicable |
- The Hong Kong Polytechnic University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- The difference in frequency of migraine attacks (the number of attacks per month)
- The proportion of responders
- Duration of headache attack
- (and 17 more...)
|
60 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT03015753 |
G-UA8P |
|
February 2016 |
April 2017 |
July 2017 |
January 10, 2017 |
January 11, 2017 |
|
- The Hong Kong Polytechnic University
Hung Hom, Hong Kong
|
|
| 3 |
NCT03484871 |
Recruiting |
Resting-state Functional Connectivity Changes During Migraine Treatment |
|
|
Observational
|
|
- Samsung Medical Center
- SK Chemicals Co.,Ltd.
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- functional MRI imaging changes
- structural MRI imaging changes
- Functional and structural correlates of treatment response
- (and 2 more...)
|
30 |
Female |
18 Years to 50 Years (Adult) |
NCT03484871 |
2016-04-028 |
|
May 2016 |
November 2018 |
November 2018 |
April 2, 2018 |
April 2, 2018 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
|
| 4 |
NCT03190044 |
Recruiting |
Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) in Migraine Prophylaxis |
|
- Dietary Supplement: PACR
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- University of Roma La Sapienza
- Gianluca Coppola
- Francesco Pierelli
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Prevention
|
- Migraine improvement in terms of responder rate
- Migraine improvement in terms of frequencies
|
82 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03190044 |
ParMig Study |
ParMig |
June 6, 2017 |
November 30, 2017 |
December 31, 2017 |
June 16, 2017 |
June 16, 2017 |
|
- Policlinico Umberto I
Rome, Italy
|
|
| 5 |
NCT02791997 |
Recruiting |
Audition After a Lesion and in Migraine. (AuditionPostLesion) |
- Migraine Disorders, Brain
|
- Other: Neuropsychological tests
- Other: Neurophysiological tests
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Percentages of correct responses in Neuropsychological tests
- reaction times in Neuropsychological tests
- Event-Related Potentials (EEG) in Neurophysiological tests
- Event-Related Fields (MEG) in Neurophysiological tests
|
335 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02791997 |
69HCL14_0202
2014-A01289-38 |
|
February 6, 2015 |
February 2019 |
February 2019 |
June 7, 2016 |
July 26, 2018 |
|
- Unité 201, Hôpital Neurologique
Bron, France - Service Explorations Fonctionnelles Neurologiques, Hôpital de la Croix-Rousse
Lyon, France
|
|
| 6 |
NCT03555214 |
Recruiting |
Efficacy of Manual Therapy for the Treatment of Migraine. |
|
- Other: Manual Therapy Group
- Other: Control group
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pain
- Frequency of pain
- Disability
- (and 5 more...)
|
40 |
All |
18 Years to 60 Years (Adult) |
NCT03555214 |
ID0024 |
MT-Migraine |
May 31, 2018 |
June 30, 2018 |
July 15, 2018 |
June 13, 2018 |
July 10, 2018 |
|
- Faculty of Physiotherapy
Valencia, Spain
|
|
| 7 |
NCT02748577 |
Recruiting |
Pain Processing in Adults With Migraines |
|
- Other: Questionnaires
- Other: Quantitative Sensory Testing (QST) Pain Measurements
|
Interventional
|
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Heat Pain Intensity coefficient and intercept from stimulus response curve
- Heat Pain Unpleasantness coefficient and intercept from stimulus response curve
- Pain Catastophizing score
- (and 13 more...)
|
98 |
All |
18 Years and older (Adult, Older Adult) |
NCT02748577 |
IRB00027845 |
|
January 2016 |
July 2020 |
July 2020 |
April 22, 2016 |
July 16, 2018 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 8 |
NCT03266588 |
Recruiting |
Open Label Safety Study in Acute Treatment of Migraine |
|
|
Interventional
|
Phase 2
Phase 3 |
- Biohaven Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the safety and tolerability of rimegepant (BHV-3000) by measuring the frequency and severity of adverse events and discontinuations due to adverse events
- ALT or AST > 3x ULN with total bilirubin >2x ULN
- hepatic related adverse events and hepatic related adverse events that lead to discontinuation
|
2000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03266588 |
BHV3000-201 |
|
August 30, 2017 |
June 2019 |
July 2019 |
August 30, 2017 |
July 12, 2018 |
|
- Central Research Associates, Inc
Birmingham, Alabama, United States - Coastal Clinical Research, Inc.
Mobile, Alabama, United States - Thunderbird Internal Medicine / Radiant Research, Inc
Glendale, Arizona, United States - (and 95 more...)
|
|
| 9 |
NCT03333109 |
Recruiting |
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients |
|
- Biological: Erenumab
- Other: Placebo
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change from baseline in monthly migraine days at the last month (Month 3) of the double-blind treatment period (DBTP)
- Achievement of at least a 50% reduction from baseline in monthly migraine days at Month 3
- Change from Baseline in acute migraine-specific medication treatment days at Month 3
- Change from Baseline in headache impact scores as measured by the HIT-6 at Month 3
|
880 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03333109 |
CAMG334A2302 |
EMPOwER |
February 8, 2018 |
February 7, 2020 |
February 7, 2020 |
November 6, 2017 |
May 11, 2018 |
|
- Novartis Investigative Site
Buenos Aires, Argentina - Novartis Investigative Site
Ciudad Autonoma de Bs As, Argentina - Novartis Investigative Site
Daejeon, Korea, Korea, Republic of - (and 10 more...)
|
|
| 10 |
NCT03108469 |
Recruiting |
Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine |
|
- Drug: IONIS-PKKRx (ISIS 546254)
- Other: Placebo
|
Interventional
|
Phase 2 |
- Smith, Timothy R., M.D.
- Clinvest Research, LLC
- Ionis Pharmaceuticals, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Comparison of Adverse Events
- Change in Migraine Days
- Change in Headache Severity
- (and 6 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03108469 |
15-001IS |
|
August 1, 2017 |
December 31, 2018 |
December 31, 2018 |
April 11, 2017 |
April 17, 2018 |
|
- StudyMetrix
Saint Peters, Missouri, United States - Clinvest Research, LLC
Springfield, Missouri, United States
|
|
| 11 |
NCT03507400 |
Recruiting |
Introvision for Migraine and Headaches |
|
- Behavioral: Introvision: mental and emotional self-regulation
|
Interventional
|
Not Applicable |
- Ludwig-Maximilians - University of Munich
- University of Hamburg
- Introvision e.V
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of headache days per month
- Headache intensity
- acute medication per month
- (and 4 more...)
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT03507400 |
IntroMig 632-15 |
IntroMig |
September 20, 2017 |
May 2019 |
May 2019 |
April 25, 2018 |
April 25, 2018 |
|
- Hospital of the Ludwig-Maximilians-University
Munich, Bavaria, Germany
|
|
| 12 |
NCT02964741 |
Recruiting |
Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo) |
|
- Device: Active Comparator
- Device: Sham Comparator
|
Interventional
|
Not Applicable |
- University of Michigan
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in pain intensity level measured by the Visual Analog Scale in migraineurs (active or sham)
- Change in mu-opioid receptor non-displaceable binding potential (BPND) in the brains of migraineurs during sustained thermal pain threshold stress challenge subsequent to treatment by HD-tDCS (active or sham).
- Change in mu-opioid receptor non-displaceable binding potential (BPND) in the brains of migraineurs at rest subsequent to treatment by HD-tDCS (active or sham).
|
90 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02964741 |
HUM00107286
R01NS094413 |
|
February 22, 2017 |
April 2020 |
June 2020 |
November 16, 2016 |
August 14, 2018 |
|
- University of Michigan School of Dentistry
Ann Arbor, Michigan, United States
|
|
| 13 |
NCT03414203 |
Recruiting |
Comparison Between Transcranial Stimulation Protocols With Continuous Current in the Chronic Migraine |
|
|
Interventional
|
Not Applicable |
- Federal University of Paraíba
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment - MIDAS
- Headache Impact Test - HIT-6
- Wechsler Intelligence Scale Letters
- (and 10 more...)
|
45 |
Female |
20 Years to 45 Years (Adult) |
NCT03414203 |
NEUROMIG |
NEUROMIG |
August 14, 2017 |
February 5, 2018 |
April 16, 2018 |
January 29, 2018 |
January 29, 2018 |
|
- Federal University of Paraiba
João Pessoa, Paraiba, Brazil
|
|
| 14 |
NCT03152305 |
Recruiting |
Intracranial Pressure During Migraine |
|
- Other: Intracranial pressure variations
|
Observational
|
|
- University Hospital, Clermont-Ferrand
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Intracranial pressure variations
- Relationships between ICP variations and clinical parameters
- Relationships between ICP variations and pain relief
|
60 |
Female |
18 Years to 50 Years (Adult) |
NCT03152305 |
CHU-331
2014-A00042-45 |
MigICP |
July 21, 2014 |
May 2017 |
July 2018 |
May 15, 2017 |
May 15, 2017 |
|
- CHU Clermont-Ferrand
Clermont-Ferrand, Auvergne, France
|
|
| 15 |
NCT03150797 |
Recruiting |
Melatonin for Adolescent Migraine Prevention Study |
|
- Drug: Melatonin
- Drug: Placebo oral capsule
|
Interventional
|
Phase 2 |
- Amy Gelfand
- University of California, Los Angeles
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo.
- Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo.
- Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo.
- (and 6 more...)
|
210 |
All |
10 Years to 17 Years (Child) |
NCT03150797 |
16-19623 |
MAP |
August 2, 2017 |
June 2021 |
June 2021 |
May 12, 2017 |
February 1, 2018 |
|
- UCLA Headache Research and Treatment Program
Los Angeles, California, United States - University of California, San Francisco, (UCSF)
San Francisco, California, United States
|
|
| 16 |
NCT02695498 |
Recruiting |
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines |
|
- Other: Mindfulness Based Stress Reduction
- Other: Migraine/stress Education
|
Interventional
|
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in frequency of migraine days from baseline
- Change in migraine duration from baseline
- Change in migraine severity-pain intensity from baseline
- (and 22 more...)
|
98 |
All |
18 Years and older (Adult, Older Adult) |
NCT02695498 |
K23AT008406 |
|
March 2016 |
May 2019 |
June 2019 |
March 1, 2016 |
July 18, 2018 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 17 |
NCT03461874 |
Not yet recruiting |
ACT Therapy for HF Migraine |
|
- Behavioral: Education of patients
- Behavioral: ACT
- Drug: Pharmacological prophylaxis
|
Interventional
|
Not Applicable |
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Brigham and Women's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction of headaches frequency
- Difference in the proportion of patients achieving the reduction of 50% or more of days with headache compared to baseline
- Medications intake
- (and 10 more...)
|
64 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03461874 |
ACT protocol |
ACTMigraine |
March 15, 2018 |
July 15, 2019 |
July 15, 2021 |
March 12, 2018 |
March 13, 2018 |
|
|
|
| 18 |
NCT03556722 |
Not yet recruiting |
Migraine Reduction Study Using Repetitive Transcranial Stimulation |
|
- Device: Repetitive Transcranial Magnetic Stimulation.
- Device: Sham rTMS
|
Interventional
|
Not Applicable |
- Universiti Putra Malaysia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline headache frequency at 3 months
- Change from baseline headache severity by Visual Analogue Scale (VAS) at 3 months
- Changes of transcranial Doppler (TCD) parameters in migraine patients in response to rTMS.
- (and 8 more...)
|
200 |
All |
18 Years to 45 Years (Adult) |
NCT03556722 |
GPB/2017/9585500 |
MRSTIMAS |
August 2018 |
August 2019 |
June 2020 |
June 14, 2018 |
June 14, 2018 |
|
- University Putra Malaysia
Serdang, Selangor, Malaysia
|
|
| 19 |
NCT02582996 |
Not yet recruiting |
Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks |
|
- Drug: Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
- Drug: Acetaminophen
|
Interventional
|
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain relief of Cefalium® compared to Tylenol®
- Pain decrease after use of investigational product, without a rescue medication
- Pain decrease after use of the investigational product, without a rescue medication
- (and 4 more...)
|
336 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02582996 |
ACH-CFL-03(01/14) |
|
April 2019 |
April 2020 |
June 2020 |
October 21, 2015 |
April 12, 2018 |
|
- Centro de Pesquisa Clínica - CPEC / Associação Obras Sociais Irmã Dulce
Salvador, Bahia, Brazil - Centro de Pesquisa Clínica Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande Do Sul, Brazil - Centro de Desenvolvimento em Estudos Clínicos Brasil - CDEC Brasil
São Paulo, Brazil - (and 3 more...)
|
|
| 20 |
NCT03275922 |
Recruiting |
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE |
|
- Drug: Placebo ZNS
- Drug: ZNS
|
Interventional
|
Phase 3 |
- IMPAX Laboratories, Inc.
- AstraZeneca
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pain-free status at 2 hours post treatment
- Proportion of subjects who achieve pain-free status at 24 hours post-dose
- Headache response at 24 hours post-dose
- Sustained headache response at 24 hours post-dose
|
426 |
All |
6 Years to 11 Years (Child) |
NCT03275922 |
IPX229-B16-01 |
|
December 4, 2017 |
April 2020 |
May 2020 |
September 8, 2017 |
August 17, 2018 |
|
- Arkansas Children's Hospital (109)
Little Rock, Arkansas, United States - Advanced Research Center, Inc (134)
Anaheim, California, United States - Sierra Medical Research (124)
Fresno, California, United States - (and 36 more...)
|
|
| 21 |
NCT02945839 |
Not yet recruiting |
Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department |
|
- Drug: Preventative Medication (PM)
- Behavioral: Enhanced Usual Care
- Behavioral: PMR (progressive muscle relaxation therapy)
|
Interventional
|
Phase 4 |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment Scale (MIDAS) at 3 Months and Baseline
- Perceived Stress Scale (PSS)
- Number of days/week treated with acute medications
- Number of drug administrations/week for acute medications
|
90 |
All |
18 Years to 64 Years (Adult) |
NCT02945839 |
16-00548 |
|
December 2018 |
December 2018 |
December 2018 |
October 26, 2016 |
May 31, 2018 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 22 |
NCT03597529 |
Recruiting
New |
CHOCOlate MeLatonin for AdolescenT MigrainE |
|
|
Interventional
|
Phase 2 |
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
100 |
All |
3 Years to 17 Years (Child) |
NCT03597529 |
17-22645 |
CHOCOLATE |
September 25, 2017 |
September 1, 2021 |
September 1, 2022 |
July 24, 2018 |
July 24, 2018 |
|
- University of California, San Francisco, (UCSF)
San Francisco, California, United States
|
|
| 23 |
NCT03081390 |
Recruiting |
Migraine and CVD Risk in Women |
|
- Other: Mixed meal tolerance testing
- Other: Skin conductance & cold pressor test
- Other: Flow-mediated dilation testing
|
Interventional
|
Not Applicable |
- University of Pennsylvania
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- LPS area under the curve (AUC)
- Flow-mediated dilation (FMD)
- Sympathetic tone at rest and with painful stimulus
|
30 |
Female |
18 Years to 35 Years (Adult) |
NCT03081390 |
826251 |
|
April 1, 2017 |
September 2018 |
September 2018 |
March 16, 2017 |
July 25, 2018 |
|
- University of Pennsylvania
Philadelphia, Pennsylvania, United States - Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
|
| 24 |
NCT02686034 |
Recruiting |
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks |
|
- Device: gammaCore-S
- Device: gammaCore-S Sham
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Treatment Response - No Pain
- Nausea/Vomiting
- Treatment Response - No Pain or Mild Pain
- Sustained Treatment Response
|
300 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02686034 |
GM-16 |
|
January 2016 |
December 2016 |
April 2017 |
February 19, 2016 |
November 28, 2016 |
|
- University Aldo Moro, Ospedale Pediatrico
Bari, Italy - IRCCS Istituto delle Scienze Neurologiche di Bologna, Ospedale Bellaria
Bologna, Italy - University Hospital of Careggi
Florence, Italy - (and 7 more...)
|
|
| 25 |
NCT02443519 |
Recruiting |
Bronx MBCT-Migraine |
|
- Behavioral: MBCT for Migraine
|
Interventional
|
Not Applicable |
- Albert Einstein College of Medicine, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment
- Headache-Related Disability Index
- Headache Days (over course of 1 month)
- (and 9 more...)
|
80 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02443519 |
2015-4684 |
BMBCT-M |
May 2015 |
September 2018 |
July 2019 |
May 14, 2015 |
January 16, 2018 |
|
- Yeshiva University
Bronx, New York, United States
|
|
| 26 |
NCT02938182 |
Not yet recruiting |
Migraine Prophylaxis With Clopidogrel Trial |
|
|
Interventional
|
Phase 4 |
- First Affiliated Hospital Xi'an Jiaotong University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from Baseline Attack Duration of Headache at three months, h
- Change from Baseline Headache Frequency per Month at three months, time
- Change from Baseline Visual Analogue Scale at three months, scores
- (and 2 more...)
|
50 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02938182 |
XJTU1AF-CRS-2016-019 |
|
October 2016 |
October 2017 |
October 2018 |
October 19, 2016 |
October 19, 2016 |
|
- First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
|
|
| 27 |
NCT03167060 |
Recruiting |
BrainCool-Migraine Intranasal Cooling Trial |
|
- Device: Active RhinoChill
- Device: Control Rhinochill
|
Interventional
|
Not Applicable |
- Cumbria Partnership NHS Foundation Trust
- BrainCool AB
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Participant is pain free at two hours following trial device treatment The patients' first treatment will be used for analysis of the superiority of the rate of patients pain free at two hours following treatment for those receiving the standard R
- Percentage of patients pain free immediately after treatment (10 minutes), at 1 hour, and 24 hours following treatment
- Headache response
- (and 3 more...)
|
90 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03167060 |
CP1628 |
|
May 8, 2017 |
September 30, 2018 |
November 30, 2018 |
May 25, 2017 |
November 8, 2017 |
|
- Neurosciences department, Penrith Hospital, Cumbria Partnership NHS Foundation Trust
Penrith, Cumbria, United Kingdom - South tees Hospital
Middlesbrough, United Kingdom - The Newcastle upon Tyne Hospitals
Newcastle upon Tyne, United Kingdom - City Hospital, Sunderland, UK
Sunderland, United Kingdom
|
|
| 28 |
NCT03481400 |
Recruiting |
CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment |
|
- Drug: Calcitonin Gene-Related Peptide
- Other: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Other
|
- Incidence of migraine
- Area under the curve of headache intensity
- Heart rate
- Blood pressure
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03481400 |
H-16014580 |
|
July 2016 |
September 2019 |
September 2019 |
March 29, 2018 |
March 29, 2018 |
|
- Danish Headache Center, Rigshospitalet Glostrup
Copenhagen, Glostrup, Denmark
|
|
| 29 |
NCT03592329 |
Not yet recruiting
New |
Vagus Nerve Stimulation and Stress Reduction Training for Migraine |
|
- Behavioral: Stress Reduction Training A
- Device: active tVNS
- Behavioral: Stress Reduction Training B
- Device: sham tVNS
|
Interventional
|
Early Phase 1 |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Brain activity changes in migraine patients in response to treatment
- Brain inflammation changes in migraine patients in response to treatment
- Brain activity differences between Migraine patients and healthy controls
- Brain inflammation differences between Migraine patients and healthy controls
|
120 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03592329 |
P01AT009965 |
|
February 2019 |
July 2023 |
July 2023 |
July 19, 2018 |
July 19, 2018 |
|
- Anthinoula A. Martinos Center
Charlestown, Massachusetts, United States
|
|
| 30 |
NCT03494673 |
Not yet recruiting |
Prediction of WMH in Migraine Using a BOLD-CVR Map |
|
- Diagnostic Test: BOLD MRI
|
Observational
|
|
- Samsung Medical Center
- National Research Foundation of Korea
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- CVR association with WMH development
- Spatial pattern of CVR
|
100 |
All |
18 Years to 50 Years (Adult) |
NCT03494673 |
2017-04-049 |
|
May 30, 2018 |
February 28, 2019 |
February 28, 2020 |
April 11, 2018 |
April 11, 2018 |
|
|
|
| 31 |
NCT03404336 |
Not yet recruiting |
Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy |
|
- Behavioral: Well-Being Therapy
- Other: Control condition
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- disability due to migraine
- frequency of migraine attacks
- duration of migraine attacks
- (and 4 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03404336 |
WBT in MIG |
|
June 1, 2018 |
May 30, 2019 |
May 30, 2019 |
January 19, 2018 |
January 19, 2018 |
|
- Fiammetta COSCI
Florence, Italy
|
|
| 32 |
NCT03499119 |
Recruiting |
AMG 334 20160172 Pediatric Migraine PK Study. |
|
- Drug: AMG 334 Dose 1
- Drug: AMG 334 Dose 2
- Drug: AMG 334 Dose 3
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Serum PK parameter of AMG 334 time to maximum observed concentration [Cmax]
- Serum PK parameter of AMG 334 time to maximum concentration [tmax]
- Serum PK parameter of AMG 334 area under the concentration time cure from 0 to 28 days [AUC 0-28days]
- (and 11 more...)
|
60 |
All |
6 Years to 17 Years (Child) |
NCT03499119 |
20160172 |
|
May 4, 2018 |
December 16, 2020 |
September 21, 2021 |
April 17, 2018 |
July 18, 2018 |
|
- Research Site
Little Rock, Arkansas, United States - Research Site
West Palm Beach, Florida, United States - Research Site
Atlanta, Georgia, United States - (and 2 more...)
|
|
| 33 |
NCT03504150 |
Recruiting |
Testing myWHI: Online Self-help Programs for Headaches |
|
- Behavioral: SPHERE
- Behavioral: PRISM
|
Interventional
|
Not Applicable |
- IWK Health Centre
- Nova Scotia Health Research Foundation
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinically significant improvement (50% reduction or greater) in number of headache days in a 4-week period from baseline to 4-months post-randomization
- Statistically significant improvement in peak headache severity in a 4-week period from baseline to 4-months post-randomization
- Statistically significant improvement in headache-related functional impairment from baseline to 4-months post-randomization
- (and 2 more...)
|
424 |
All |
14 Years to 40 Years (Child, Adult) |
NCT03504150 |
1022640 |
|
May 4, 2018 |
October 1, 2019 |
May 1, 2020 |
April 20, 2018 |
August 14, 2018 |
|
- IWK Health Centre
Halifax, Nova Scotia, Canada
|
|
| 34 |
NCT03465904 |
Recruiting |
A Phase III Trial of e-TNS for the Acute Treatment of Migraine |
|
- Device: Verum Cefaly® Abortive Program device
- Device: Sham Cefaly® Abortive Program device
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pain Freedom at 2 hours
- Most bothersome migraine-associated symptom freedom at 2 hours
- Pain Relief at 2 hours
- (and 4 more...)
|
600 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03465904 |
51401 |
TEAM |
April 10, 2018 |
October 2018 |
October 2018 |
March 14, 2018 |
July 6, 2018 |
|
- Clinical Research Consortium
Tempe, Arizona, United States - Pharmacology Research Institute
Encino, California, United States - Yale University
New Haven, Connecticut, United States - (and 7 more...)
|
|
| 35 |
NCT03559257 |
Recruiting |
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change from Baseline in the Number of Monthly Migraine Headache Days
- Mean Change from Baseline in the Number of Monthly Migraine Headache Days in Participants with Episodic Migraine
- Percentage of Participants with ≥50% Reduction from Baseline in Monthly Migraine Headache Days
- (and 10 more...)
|
420 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03559257 |
16670
I5Q-MC-CGAW
2018-000600-42 |
CONQUER |
July 31, 2018 |
July 10, 2019 |
October 31, 2019 |
June 18, 2018 |
August 8, 2018 |
|
- 21st Century Neurology
Phoenix, Arizona, United States - Medical Center for Clinical Research
San Diego, California, United States - California Medical Clinic for Headache
Santa Monica, California, United States - (and 77 more...)
|
|
| 36 |
NCT02315833 |
Recruiting |
The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients |
|
- Drug: Acetium
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Biohit Oyj
- The Finnish Funding Agency for Technology and Innovation (TEKES)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of migraine attacks (NMA) per evaluation interval
- Number of migraine days (NMD) per evaluation period
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02315833 |
AC-MIGPREV-1 |
|
June 2014 |
December 2017 |
December 2017 |
December 12, 2014 |
June 23, 2017 |
|
- Terveystalo, Kamppi
Helsinki, Finland - Lääkärikeskus Aava, Helsingin Päänsärkykeskus Oy
Helsinki, Finland - Terveystalo, Jyväskylä
Jyväskylä, Finland - (and 2 more...)
|
|
| 37 |
NCT03559088 |
Recruiting |
A Study of the Effect of a Disease-Specific Migraine Smart Phone Application (App) on Participant Care |
|
|
Interventional
|
Not Applicable |
- Eli Lilly and Company
- Atrium Health
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Number of Participants Receiving a Preventive Migraine Prescription
- Number of Months of App Use
- Number of Participants Receiving Acute and Preventive Migraine Treatments, Opioids, Barbiturates
- (and 6 more...)
|
200 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03559088 |
17129
I5Q-MC-CGBA |
|
June 11, 2018 |
July 2019 |
July 2020 |
June 15, 2018 |
July 19, 2018 |
|
- Charlotte Medical Clinic
Charlotte, North Carolina, United States - Charlotte Internal Medicine
Charlotte, North Carolina, United States - Charlotte Medical Group
Charlotte, North Carolina, United States - (and 2 more...)
|
|
| 38 |
NCT03398668 |
Recruiting |
Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine |
|
- Device: Relievion device- Treatment stimulation
- Device: Relievion Device- Sham stimulation
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change of pain score (measured on a visual analog scale=VAS) at 1 hour compared to baseline
- Mean change of pain score (measured by VAS) at 2 hours compared to baseline (if rescue therapy was not used).
- Mean change of pain score (measured by VAS) at 24 hours compared to baseline (if rescue therapy was not used).
- (and 4 more...)
|
58 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03398668 |
SP301 |
|
February 22, 2018 |
October 30, 2018 |
October 30, 2018 |
January 12, 2018 |
July 6, 2018 |
|
- Laniado Medcial Center
Netanya, Israel
|
|
| 39 |
NCT03459495 |
Not yet recruiting |
Therapeutic Ultrasound in the Treatment of Migraine |
|
- Device: therapeutic ultrasound
- Device: placebo ultrasound
|
Interventional
|
Not Applicable |
- Bursa Yüksek İhtisas Education and Research Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Numeric rating scale (NRS)
- Migraine Disability Assessment Questionnaire Score (MIDAS)
- paracetamol consumption
- the number of migraine attacks per month.
|
58 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT03459495 |
2011-KAEK-2018-1/25 |
|
March 10, 2018 |
September 10, 2018 |
September 10, 2018 |
March 9, 2018 |
March 9, 2018 |
|
|
|
| 40 |
NCT02681211 |
Recruiting |
Auricular Acupuncture vs SOC in Migraine HA |
|
- Other: Auricular Acupuncture
- Drug: Ketorolac 0.5mg/kg, max 30mg
- Drug: Metoclopramide 0.1 mg/kg, max 10mg
- (and 2 more...)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in baseline pain score by a numerical self-reported visual analog pain score (VAS)
- Duration of pain relief using the VAS pain scale
|
80 |
All |
8 Years to 18 Years (Child, Adult) |
NCT02681211 |
15.0827 |
MigAcu |
February 2016 |
December 2018 |
June 2019 |
February 12, 2016 |
June 8, 2018 |
|
- Norton Children's Hospital
Louisville, Kentucky, United States - Norton Children's Medical Center
Louisville, Kentucky, United States
|
|
| 41 |
NCT03099070 |
Recruiting |
Acute Stress Response in Migraine Sufferers |
|
- Behavioral: Stress
- Other: Fasting
|
Interventional
|
Not Applicable |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Headache/Medication Use
- Time to next headache attack
- Medication use
- Pain Scores
|
212 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03099070 |
2016P001834 |
|
March 8, 2017 |
May 31, 2020 |
May 31, 2020 |
April 4, 2017 |
April 4, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 42 |
NCT03488563 |
Recruiting |
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine |
|
- Biological: B244
- Biological: Vehicle
|
Interventional
|
Phase 2 |
- AOBiome LLC
- Veristat, Inc.
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Mean change in monthly migraine days.
- Mean change in monthly migraine attacks.
- (and 5 more...)
|
303 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03488563 |
MGB244-001 |
|
March 30, 2018 |
November 20, 2018 |
November 20, 2018 |
April 5, 2018 |
June 26, 2018 |
|
- Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States - Collaborative Neuroscience Network, LLC
Long Beach, California, United States - CI Trials
Riverside, California, United States - (and 12 more...)
|
|
| 43 |
NCT03263897 |
Recruiting |
Feasibility of Using a Mobile Device Controlled Micro-pressure Pulse Insufflator for Acute Migraine Relief |
|
- Device: insufflation
- Device: placebo insufflation
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Changes in Symptoms severity scale
- Changes in pain level
- Changes in Symptoms severity scale at 2 hours
- (and 3 more...)
|
50 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT03263897 |
CI-IRB-20170814001 |
|
August 21, 2017 |
August 2018 |
April 2019 |
August 28, 2017 |
April 26, 2018 |
|
- YRMC: Physiatry, Neurosurgery, Neurology Clinic
Prescott, Arizona, United States - FNOR Clinic Scottsdale
Scottsdale, Arizona, United States
|
|
| 44 |
NCT03159000 |
Recruiting |
A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks |
|
- Drug: Saline
- Combination Product: lidocaine/bupivacaine
|
Interventional
|
Phase 4 |
- Thomas Jefferson University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of subjects experiencing headache improvement at 2 hours
- Percentage of subjects experiencing headache improvement 10 minutes
- Percentage of subjects experiencing headache improvement at 30 minutes
- (and 7 more...)
|
50 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03159000 |
GON/WBY/003 |
|
May 1, 2017 |
December 31, 2017 |
June 30, 2018 |
May 18, 2017 |
May 18, 2017 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
|
| 45 |
NCT03083860 |
Not yet recruiting |
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. |
|
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- Evaluation of correlation of attention-related electrophysiological changes and patients' migraine dynamics based at-home EEG measurements via mobile phone app.
|
100 |
All |
18 Years to 50 Years (Adult) |
NCT03083860 |
CLD10 |
|
September 2017 |
April 2018 |
December 2018 |
March 20, 2017 |
June 16, 2017 |
|
|
|
| 46 |
NCT03303105 |
Recruiting |
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine |
|
|
Interventional
|
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with Adverse Events
- Mean change from baseline in the number of migraine days
- Mean change from baseline in the monthly average of migraine days
- (and 2 more...)
|
40 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03303105 |
406-102-00003
JapicCTI-173726 |
|
January 4, 2018 |
February 2020 |
February 2020 |
October 5, 2017 |
February 16, 2018 |
|
|
|
| 47 |
NCT03453203 |
Not yet recruiting |
Treatment of Cervical Pain in Chronic Migraine |
|
- Other: Osteopathic Manipulative Treatment Using Counterstrain
|
Interventional
|
Not Applicable |
- University Hospitals Cleveland Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Treatment
|
- Treatment of Cervical Pain in Chronic Migraine
|
30 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03453203 |
UHClevelandMC1 |
|
April 29, 2018 |
December 29, 2018 |
December 29, 2018 |
March 5, 2018 |
March 7, 2018 |
|
|
|
| 48 |
NCT03303079 |
Recruiting |
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine |
|
- Drug: TEV-48125
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change from baseline in the monthly (28-day) average number of headache days of at least moderate severity during the 12-week period after the first dose of Interventional Medicinal Product(IMP)
- Proportion of patients reaching at least 50% reduction in the monthly average number of headache days of at least moderate severity
- Mean change from baseline in the monthly average number of days of use of any acute migraine medications
- (and 2 more...)
|
540 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03303079 |
406-102-00001
JapicCTI-173723 |
|
December 19, 2017 |
April 2019 |
April 2019 |
October 5, 2017 |
February 16, 2018 |
|
|
|
| 49 |
NCT03303092 |
Recruiting |
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine |
|
- Drug: TEV-48125
- Drug: Placebos
|
Interventional
|
Phase 2
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change from baseline in the monthly (28-day) average number of migraine days during the 12-week period after the first dose of Interventional Medicinal Product
- Proportion of patients reaching at least 50% reduction in the monthly average number of migraine days
- Mean change from baseline in the monthly average number of days of use of any acute migraine medications relative to baseline
- Mean change from baseline in the number of migraine days
|
330 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03303092 |
406-102-00002
JapicCTI-173725 |
|
December 19, 2017 |
December 2018 |
December 2018 |
October 5, 2017 |
February 16, 2018 |
|
|
|
| 50 |
NCT02593097 |
Recruiting |
Metformin for the Prevention of Episodic Migraine (MPEM) |
|
- Drug: Metformin
- Drug: Matching Placebo
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The reduction in the number of migraine days per month during 12 weeks of treatment with metformin vs placebo (primary end point).
- The response rate (percentage of patients with a >50% reduction in migraine days per month) during 12 weeks of treatment with metformin vs placebo (secondary end point).
- Number of participants with treatment-related adverse events
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02593097 |
15-000422 |
MPEM |
February 2016 |
December 2017 |
December 2018 |
October 30, 2015 |
October 30, 2017 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
|
|
| 51 |
NCT02725554 |
Not yet recruiting |
Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine |
|
- Device: StimRelieve Halo System
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Headache Days
- Adverse Events
- Migraine Days
- (and 2 more...)
|
144 |
All |
18 Years and older (Adult, Older Adult) |
NCT02725554 |
30-00070 |
|
January 2019 |
December 2020 |
December 2021 |
April 1, 2016 |
April 19, 2018 |
|
|
|
| 52 |
NCT02665273 |
Recruiting |
Greater Occipital Nerve Block With Bupivacaine for Acute Migraine |
|
- Procedure: Greater occipital nerve block
- Procedure: Sham
|
Interventional
|
Phase 4 |
- Montefiore Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Headache freedom
- Sustained headache relief
- Satisfaction
|
78 |
All |
18 Years and older (Adult, Older Adult) |
NCT02665273 |
2015-4754 |
|
July 1, 2015 |
May 2018 |
May 2018 |
January 27, 2016 |
December 12, 2017 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
|
| 53 |
NCT02583581 |
Recruiting |
Evaluation of Use of Brain Activity Monitoring for Prediction of Migraine Attacks |
|
- Device: EEG monitoring (MindWave by NeuroSky)
- Device: EEG monitoring (EPOC by Emotiv)
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Measurements of brain electrical signal in Micro volt.
|
50 |
All |
18 Years to 50 Years (Adult) |
NCT02583581 |
CLD4 |
|
October 2015 |
January 2018 |
February 2018 |
October 22, 2015 |
June 16, 2017 |
|
- Rambam Medical Center
Haifa, Israel
|
|
| 54 |
NCT03096834 |
Recruiting |
A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies |
|
- Biological: Pre-Filled Syringe (PFS)
- Biological: Placebo Pre-Filled Syringe (PFS)
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Percentage of patients with a 50% response in the reduction of Monthly Migraine Days (MMD)
- Change in the number of monthly migraine days (MMDs) from baseline to month 3
- Change in the Migraine Physical Function Impact Diary (MPFID) "impact on everyday activities" domain score from baseline to month 3
- (and 4 more...)
|
220 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03096834 |
CAMG334A2301
2016-002211-18 |
LIBERTY |
March 20, 2017 |
January 18, 2018 |
January 19, 2021 |
March 30, 2017 |
June 28, 2018 |
|
- Novartis Investigative Site
Heidelberg, Australia - Novartis Investigative Site
Innsbruck, Austria - Novartis Investigative Site
Vienna, Austria - (and 68 more...)
|
|
| 55 |
NCT03395457 |
Not yet recruiting |
Tertiary Care With or Without Manual Therapy for Chronic Migraine |
|
- Drug: Care as usual
- Other: Manual Therapy
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in migraine-related disability
- Change in Migraine Specific Quality of Life Questionnaire Score (MSQoL 2.1)
- Headache Frequency
|
70 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03395457 |
Bournemouth 228901 |
|
August 13, 2018 |
December 1, 2018 |
December 1, 2018 |
January 10, 2018 |
July 11, 2018 |
|
|
|
| 56 |
NCT03526874 |
Not yet recruiting |
Occipital Blocks for Acute Migraine |
- Chronic Migraine, Headache
- Episodic Migraine
|
- Drug: Lidocaine 4% Topical Application Cream [LMX 4]
- Drug: Lidocaine Hydrochloride 2 mg/mL Injectable Solution
- Drug: Normal Saline
|
Interventional
|
Phase 3 |
- Children's Hospital of Philadelphia
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change in Pain Intensity Scores
- Change from Baseline Disability
- Percentage of Subjects with Pain Freedom
- (and 3 more...)
|
58 |
All |
7 Years to 17 Years (Child) |
NCT03526874 |
18-014939 |
|
September 2018 |
November 2021 |
December 2021 |
May 16, 2018 |
August 8, 2018 |
|
- Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
|
| 57 |
NCT03432286 |
Recruiting |
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in the Number of Monthly Migraine Headache Days
- Proportion of Participants with Reduction from Baseline ≥50% in Monthly Migraine Headache Days
- Change from Baseline in the Number of Monthly Headache Days with Nausea and/or Vomiting
- (and 13 more...)
|
224 |
All |
6 Years to 17 Years (Child) |
NCT03432286 |
16352
I5Q-MC-CGAS
2017-004351-23 |
REBUILD |
March 14, 2018 |
December 1, 2021 |
December 26, 2022 |
February 14, 2018 |
August 14, 2018 |
|
- Medical Center for Clinical Research
San Diego, California, United States - Clinical Neuroscience Solutions Inc
Jacksonville, Florida, United States - Psychiatric Inst of Florida-Clinical Neuroscience Solutions
Orlando, Florida, United States - (and 12 more...)
|
|
| 58 |
NCT02706015 |
Not yet recruiting |
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks |
|
- Drug: Cefaliv® & Placebo
- Drug: Neosaldina® & Placebo
|
Interventional
|
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Evaluate the efficacy and non-inferiority of Cefaliv® compared to Neosaldina® in pain relief
- The remission of the pain after use of the investigational product, without use of a rescue medication;
- The relief of pain after use of the investigational product, without use of a rescue medication;
- (and 3 more...)
|
216 |
All |
18 Years to 66 Years (Adult, Older Adult) |
NCT02706015 |
ACH-CFL-03(10/14) |
|
October 2020 |
May 2021 |
July 2021 |
March 11, 2016 |
April 9, 2018 |
|
- Ache Laboratorios Farmaceuticos
Guarulhos, São Paulo, Brazil
|
|
| 59 |
NCT03576820 |
Not yet recruiting |
Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department |
|
- Drug: Lidocaine
- Drug: Placebo
|
Interventional
|
Phase 3 |
- New York City Health and Hospitals Corporation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Pain Score
- The Number of Subjects with Improvement of Associated Symptoms
- The Number of Subjects Who Receive IV Pain Medications
- (and 3 more...)
|
50 |
All |
10 Years to 20 Years (Child, Adult) |
NCT03576820 |
2018-9278 |
|
August 2018 |
August 2019 |
December 2019 |
July 3, 2018 |
July 6, 2018 |
|
- Jacobi Medical Center
Bronx, New York, United States
|
|
| 60 |
NCT03400059 |
Recruiting |
Study to Evaluate the Efficacy of Intranasal Kinetic Oscillation Stimulation in the Preventive Treatment of Chronic Migraine |
|
- Device: Chordate System S211 in treatment mode
- Device: Chordate System S211 in placebo mode
|
Interventional
|
Not Applicable |
- Chordate Medical
- Vinnova (Swedish Governmental Agency for Innovation Systems)
- FGK Clinical Research GmbH
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Mean change from Baseline (4-week screening period) in monthly headache days with moderate to severe intensity in 4-week performance assessment period (V3 to V7).
- Mean change from Baseline in monthly headache days with moderate to severe intensity in follow-up period
- Mean change from Baseline in monthly migraine days
- (and 8 more...)
|
140 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03400059 |
PM007 |
|
March 22, 2018 |
July 2019 |
July 2019 |
January 17, 2018 |
July 18, 2018 |
|
- Neurologie- & Kopfschmerzzentrum
München, Bayern, Germany - Klinikum Großhadern / Neurologische Klinik der Universität München
München, Bayern, Germany - Migräne-Klinik Königstein
Königstein Im Taunus, Hessen, Germany - CTC North am Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
|
|
| 61 |
NCT02765581 |
Recruiting |
Efficacy Study of Acupuncture in the Prevention of Migraine Without Aura |
|
- Device: Verum acupuncture
- Device: Sham acupuncture
- Behavioral: Usual care
|
Interventional
|
Not Applicable |
- Wei Wang
- Hubei College of Traditional Chinese Medicine
- Hubei Hospital of Traditional Chinese Medicine
- (and 6 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in the number of migraine days
- Change in the frequency of migraine attacks
- The proportion of responders
- (and 7 more...)
|
150 |
All |
15 Years to 65 Years (Child, Adult, Older Adult) |
NCT02765581 |
201403RCTMWA |
|
May 1, 2016 |
December 31, 2018 |
June 30, 2019 |
May 6, 2016 |
June 1, 2018 |
|
- Department of Neurology of Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, China
|
|
| 62 |
NCT03338920 |
Recruiting |
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents |
- Acute Migraine With or Without Aura
|
- Drug: sumatriptan nasal powder
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of participants who were headache pain free at 120 minutes after treatment
- Number of participants with headache relief at 120 minutes after treatment
- Number of participants who were headache pain free any time after treatment
- (and 9 more...)
|
420 |
All |
12 Years to 17 Years (Child) |
NCT03338920 |
17-AVP-825-301 |
|
November 2, 2017 |
November 2019 |
November 2019 |
November 9, 2017 |
July 11, 2018 |
|
- Phoenix Children's Hospital
Phoenix, Arizona, United States - Fullerton Neurology and Headache Center
Fullerton, California, United States - Alpine Clinical Research Center, Inc.
Boulder, Colorado, United States - (and 24 more...)
|
|
| 63 |
NCT02358681 |
Recruiting |
Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children |
|
- Drug: Ketorolac, intranasal
- Drug: Ketorolac, intravenous
- Drug: Placebo, intravenous
- Drug: Placebo, intranasal
|
Interventional
|
Phase 3 |
- Columbia University
- Migraine Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in pain score after analgesic administration (Faces Pain Scale - Revised (FPS-R)
- Time to achieve clinically significant reduction in pain after analgesic administration (Pain score)
|
80 |
All |
8 Years to 17 Years (Child) |
NCT02358681 |
AAAO1302 |
|
May 2015 |
December 2019 |
December 2019 |
February 9, 2015 |
April 10, 2018 |
|
- NewYork Presbyterian Morgan Stanley Children's Hospital
New York, New York, United States
|
|
| 64 |
NCT03598075 |
Recruiting
New |
Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients |
|
- Other: Amylin (Pramlintide)
- Other: CGRP
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Headache intensity
- Headache characteristics
- Dilatation of Arteria radialis and arteria temporalis superficialis
- (and 2 more...)
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT03598075 |
H-17035931 |
|
July 1, 2018 |
July 1, 2019 |
July 1, 2019 |
July 25, 2018 |
August 7, 2018 |
|
- Danish Headache Center
Glostrup, Denmark
|
|
| 65 |
NCT02795351 |
Recruiting |
Induction of Migraine Aura With Sildenafil |
|
- Drug: Sildenafil
- Drug: Placebo
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Aura and migraine like headache
- Markers of endothelial function in blood
- Migraine without aura
|
16 |
All |
18 Years to 50 Years (Adult) |
NCT02795351 |
H-15008491 |
|
June 2015 |
June 2018 |
August 2018 |
June 10, 2016 |
March 22, 2018 |
|
- Department of Neurology, Herlev-Gentofte Hospital
Herlev, Denmark
|
|
| 66 |
NCT03220113 |
Recruiting |
Treatment of Chronic Migraine Headaches. |
- Chronic Migraine Without Aura, Intractable
- Migraine With Typical Aura
- Migraine Disorders
|
- Combination Product: Dexamethasone, Lidocaine, Thiamine cohort
|
Interventional
|
Phase 1
Phase 2 |
- Corona Doctors Medical Clinics, Inc.
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assessment of the safety to the De-Novo treatment formula in study patients
- Assessment of the clinical response to the De-Novo treatment formula in study patients consisting of a lone composite measure
|
100 |
All |
10 Years to 90 Years (Child, Adult, Older Adult) |
NCT03220113 |
2017/05/1 |
Migraine |
July 1, 2017 |
July 1, 2018 |
July 1, 2019 |
July 18, 2017 |
April 4, 2018 |
|
- Corona Doctors Medical Clinics Inc
Corona, California, United States
|
|
| 67 |
NCT03570086 |
Not yet recruiting |
Multiparametric Diagnostic Model of Thick-section Clinical-quality MRI Data in Detecting Migraine Without Aura |
|
- Diagnostic Test: diagnostic
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- accuracy
- sensitivity
- specificity
|
400 |
All |
21 Years to 55 Years (Adult) |
NCT03570086 |
20170908010418 |
|
July 1, 2018 |
December 30, 2018 |
December 30, 2019 |
June 26, 2018 |
June 26, 2018 |
|
- Xijing Hospital
Xi'an, Shaanxi, China
|
|
| 68 |
NCT03097536 |
Recruiting |
Migraine and Homeostasis:What Can we Learn From Glucose |
|
|
Interventional
|
Not Applicable |
- Beth Israel Deaconess Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The difference in blood glucose on days with migraine compared to blood glucose on days without migraine
- The primary outcome is the change in pain score from the time of pain plateau to the pain score at 120 minutes as measured by a visual analogue scale.
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03097536 |
2015P000419 |
|
March 2016 |
June 2020 |
January 2021 |
March 31, 2017 |
June 4, 2018 |
|
- Beth Israel Deaconess Medial Center
Boston, Massachusetts, United States
|
|
| 69 |
NCT03543254 |
Recruiting |
"Follow the Sutures". A New Procedure for Injection of Botulinum Toxin for Chronic Migraine |
- Migraine Disorders
- Chronic Disease
|
|
Interventional
|
Phase 2 |
- Norwegian University of Science and Technology
- St. Olavs Hospital
- Mayo Clinic
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of adverse events
- moderate-severe headache days 5-8 weeks after injection compared with baseline
|
40 |
All |
18 Years to 64 Years (Adult) |
NCT03543254 |
2017/1490
2017-002516-13 |
|
June 1, 2018 |
May 2020 |
May 2020 |
June 1, 2018 |
June 12, 2018 |
|
- Mayo Clinic, 13400 E. Shea Blvd
Scottsdale, Arizona, United States - St Olavs Hospital
Trondheim, Norway
|
|
| 70 |
NCT02643719 |
Recruiting |
Migraine Treatment in ED |
|
- Behavioral: Relaxation Therapy
- Drug: Topiramate
- Drug: Standard of Care
- Drug: Abortive Medication (Naproxen and Sumatriptan)
|
Interventional
|
Not Applicable |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Verbal numeric rating scale (VNRS) scores
- Headache Impact Test (HIT) scores
|
100 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02643719 |
14-01981 |
|
December 2015 |
December 2018 |
December 2018 |
December 31, 2015 |
December 6, 2017 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 71 |
NCT03419715 |
Recruiting |
Topical Bimatoprost in the Treatment of Migraine |
- Migraine Disorders
- Headache Disorders
|
- Drug: Bimatoprost Topical Solution
- Drug: Control
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Reduction in Headache Frequency
- Intensity of Headaches
- Duration of Headaches
- Migraine Disability Assessment Scale (MIDAS)--Quality of Life
|
80 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03419715 |
17-MAN-001 |
|
January 5, 2018 |
December 2018 |
December 2018 |
February 2, 2018 |
August 15, 2018 |
|
- New England Regional Headache Center
Worcester, Massachusetts, United States - Omega Medical Research
Warwick, Rhode Island, United States
|
|
| 72 |
NCT02120326 |
Recruiting |
Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine |
- Chronic Migraine as Defined by Criteria of International Headache Society (IHS)
|
- Device: Transcranial direct current stimulation of the motor cortex
- Device: simulation of Transcranial direct current stimulation of the motor cortex
|
Interventional
|
Not Applicable |
- University Hospital, Grenoble
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Comparison of the evolution of seizure frequency between the two groups
- Comparison of the evolution of seizure severity between the two groups
- Comparison of the evolution of crisis treatment use between the two groups
- (and 4 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02120326 |
DCIC13/48 |
Medis |
May 5, 2014 |
December 2018 |
December 2018 |
April 22, 2014 |
May 3, 2017 |
|
- Grenoble University Hospital
Grenoble, Isere, France - Hospital of Voiron
Voiron, Isere, France
|
|
| 73 |
NCT03036761 |
Recruiting |
Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines |
|
- Procedure: Auriculotherapy
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of days with migraine and headache
- Number of days with migraine
- Number of days with non migrainous headache
|
90 |
Female |
18 Months to 80 Years (Child, Adult, Older Adult) |
NCT03036761 |
2016/58
2016-A01534-47 |
Migauric |
January 2017 |
May 2019 |
December 2019 |
January 30, 2017 |
March 1, 2017 |
|
- Hopital Foch
Suresnes, France
|
|
| 74 |
NCT02903680 |
Recruiting |
RCT of IV Dexamethasone to Prevent Relapse in the Treatment of Migraine in a Paediatric ED |
|
- Drug: Dexamethasone group
- Drug: Placebo group
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- incidence of relapse following discharge from the ED
- mean level of pain
- associated symptoms (i.e. nausea, vomiting, photophobia and sonophobia),
- (and 2 more...)
|
116 |
All |
8 Years to 18 Years (Child, Adult) |
NCT02903680 |
3662 |
|
May 2014 |
May 2019 |
June 2019 |
September 16, 2016 |
October 20, 2017 |
|
- CHU Sainte Justine
Montréal, Quebec, Canada
|
|
| 75 |
NCT03280342 |
Recruiting |
Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine |
|
- Drug: IR-TPM (Topamax)
- Drug: XR-TPM (Trokendi XR)
|
Interventional
|
Phase 2 |
- University of Minnesota - Clinical and Translational Science Institute
- Supernus Pharmaceuticals, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Controlled Oral Word Association Test (COWA)-generative phonemic fluency
- Measures of semantic verbal fluency
- Digit Span Backward
- (and 2 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03280342 |
CETIM |
|
October 30, 2017 |
June 2018 |
June 2019 |
September 12, 2017 |
November 14, 2017 |
|
- University of Minnesota
Minneapolis, Minnesota, United States - Prism Research
Saint Paul, Minnesota, United States
|
|
| 76 |
NCT02720211 |
Recruiting |
Spectacle Tints and Thin-Films for Migraine |
- Headache Migraine Chronic
|
- Device: Gray tinted spectacle lenses
- Device: Thin-Film spectacle lenses
|
Interventional
|
Not Applicable |
- University of Utah
- Axon Optics, LLC
- Mayo Clinic
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Headache frequency
- Headache Impact
|
140 |
All |
18 Years to 60 Years (Adult) |
NCT02720211 |
IRB #86498 |
|
August 2016 |
July 2018 |
October 2018 |
March 25, 2016 |
November 17, 2017 |
|
- Mayo Clinic
Phoenix, Arizona, United States - Brigham and Women's Hospital; John R Graham Headache Center; Harvard University,
Boston, Massachusetts, United States - Headache Center of the Neuroscience Institute; Hofstra Northwell Health; Northshore University Hospital
Great Neck, New York, United States - John A Moran Eye Center; University of Utah Hospitals and Clinics
Salt Lake City, Utah, United States
|
|
| 77 |
NCT03026101 |
Recruiting |
Understanding the Pathophysiology of Migraine Pain |
- Migraine Disorders
- Migraine, Classic
- Migraine Without Aura
|
|
Interventional
|
Not Applicable |
- Montefiore Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Migraine
- Migraine log pre-procedure: severity measure
- Migraine log pre-procedure: frequency measure
- (and 17 more...)
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03026101 |
2017-8335 |
|
January 2017 |
January 2019 |
June 2019 |
January 20, 2017 |
April 24, 2018 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
|
| 78 |
NCT03557333 |
Not yet recruiting |
Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP-301) |
|
- Combination Product: INP104
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serious treatment emergent adverse events (SAEs)
- Non-serious treatment emergent adverse events (AEs)
- Change in nasal mucosa
- Change in olfactory function
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03557333 |
INP104-301 |
|
July 31, 2018 |
July 2, 2019 |
July 2, 2019 |
June 15, 2018 |
June 29, 2018 |
|
|
|
| 79 |
NCT02969642 |
Recruiting |
Study of Low-level Laser Therapy in the Acute Treatment of Migraine |
|
- Device: Argus Migraine Treatment device
|
Interventional
|
Phase 2 |
- The San Francisco Clinical Research Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Differences between treatment groups in pain free rates at 2 hours post treatment.
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02969642 |
AP 1001 |
|
March 2016 |
May 2017 |
July 2017 |
November 21, 2016 |
December 2, 2016 |
|
- San Francisco Clinical Research Center
San Francisco, California, United States
|
|
| 80 |
NCT02485418 |
Recruiting |
Low- Dose Propofol Infusion as an Abortive Treatment for Migraine Headaches in Pediatric Patients |
|
|
Interventional
|
Not Applicable |
- University of Texas Southwestern Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in Headache Pain Score
- Duration of analgesia
- Total propofol dose
|
40 |
All |
7 Years to 18 Years (Child, Adult) |
NCT02485418 |
Propofol2014 |
|
June 2015 |
October 2017 |
|
June 30, 2015 |
October 27, 2016 |
|
- Children's Health Children's Medical Center Dallas
Dallas, Texas, United States
|
|
| 81 |
NCT03578354 |
Not yet recruiting |
4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine |
- Vestibular Migraine
- Migraine Disorders
- Vestibular Diseases
|
- Drug: 4-aminopyridine
- Drug: Atenolol
- Other: Placebo
|
Interventional
|
Phase 2 |
- Massachusetts Eye and Ear Infirmary
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Dizziness Handicap Score
- Change in number of dizziness episodes
- Change in motion sickness susceptibility
- (and 5 more...)
|
219 |
All |
18 Years and older (Adult, Older Adult) |
NCT03578354 |
Pending |
|
January 2019 |
January 2023 |
January 2024 |
July 6, 2018 |
July 6, 2018 |
|
- Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States
|
|
| 82 |
NCT03022838 |
Recruiting |
The Effects of Caffeine Withdrawal on Migraine |
- Migraine
- Caffeine Withdrawal
|
|
Interventional
|
Phase 2
Phase 3 |
- Nordlandssykehuset HF
- King's College London
- University Hospital of North Norway
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Migraine days
- Withdrawal symptoms and/or syndrome (according to criteria)
- Migraine attacks
- (and 2 more...)
|
80 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03022838 |
2015/1729REK |
|
February 28, 2017 |
February 28, 2019 |
November 2019 |
January 18, 2017 |
December 29, 2017 |
|
- Nordland Hospital
Bodø, Norway - Departement of Neurology, NLSH HF
Bodø, Norway - Departement of Neurology
Tromsø, Norway
|
|
| 83 |
NCT03361423 |
Recruiting |
Evaluation of a Novel Device for Treatment of Migraine Headache |
- Migraine Without Aura
- Migraine With Aura
|
- Device: Nerivio Migra-1 active device
- Device: Nerivio Migra-1 Sham device
|
Interventional
|
Not Applicable |
- Theranica
- Rambam Health Care Campus
- Northwell Health
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of reduction of migraine headache post 2 hours from treatment
- Percentage of reduction of most bothersome migraine-associated symptom (MBS) relief post 2 hours treatment
- Percentage of reduced Migraine Headache AND MBS Relief post 2 hours post tresatment
- Percentage of pain disappearance 2 hours post treatment
|
270 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03361423 |
TCH003 |
|
December 17, 2017 |
June 30, 2018 |
August 30, 2018 |
December 4, 2017 |
July 3, 2018 |
|
- Hartford Headache Center
Hartford, Connecticut, United States - Mercy Hospital
Saint Louis, Missouri, United States - Clinvest Research
Springfield, Missouri, United States - (and 9 more...)
|
|
| 84 |
NCT03337620 |
Recruiting |
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine |
|
|
Interventional
|
Phase 3 |
- Tian Medical Inc.
- TAMM Net, Inc.
- Clinvest Research, LLC
- New England Institute for Clinical Research
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Number of Migraine Headaches During Treatment Phase
- Change in Number of Migraine Headache Days Post-Treatment
- Safety/Tolerability of TX360 Device Based on Adverse Effects
|
180 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03337620 |
16-001TI |
|
September 20, 2017 |
January 1, 2019 |
June 1, 2019 |
November 9, 2017 |
March 5, 2018 |
|
- Hartford Headache Center
East Hartford, Connecticut, United States - Waterbury Neurology
Middlebury, Connecticut, United States - Yale University
New Haven, Connecticut, United States - (and 5 more...)
|
|
| 85 |
NCT03055767 |
Recruiting |
Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population |
- Migraine Disorders
- Headache, Migraine
- Pediatrics
|
- Drug: OnabotulinumtoxinA
- Other: Placebo (Saline)
|
Interventional
|
Phase 2 |
- University of California, Irvine
- American Society of Regional Anesthesia
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Pain scores (Intensity)
- Change in duration of migraine episode
- Frequency of Migraine
- (and 8 more...)
|
26 |
All |
8 Years to 17 Years (Child) |
NCT03055767 |
UCIANES09 |
|
March 1, 2017 |
December 2019 |
March 2020 |
February 16, 2017 |
May 7, 2018 |
|
- Gottschalk Medical Plaza
Irvine, California, United States - UC Irvine Medical Center
Orange, California, United States
|
|
| 86 |
NCT03465826 |
Not yet recruiting |
Developing a Mobile Health Pain-Coping Skills Training Program for the Treatment of Chronic Migraine: AIM 4 |
- Chronic Migraine, Headache
|
- Behavioral: PainCOACH Pain Coping Skills Training
- Behavioral: Treatment as Usual
|
Interventional
|
Not Applicable |
- Wake Forest University Health Sciences
- Duke University
- Hackensack University Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Feasibility and Engagement
- Change in Migraine Disability
- Change in HIT-6
- (and 4 more...)
|
144 |
All |
18 Years and older (Adult, Older Adult) |
NCT03465826 |
18-01218 |
|
May 1, 2021 |
February 28, 2023 |
November 30, 2023 |
March 14, 2018 |
March 14, 2018 |
|
|
|
| 87 |
NCT03471039 |
Recruiting |
PACAP27 Headache Properties in Migraine Without Aura Patients |
|
- Drug: PACAP27
- Drug: Saline
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Health Services Research
|
- Headache Scores
- Facial blood flow (flushing)
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT03471039 |
H-17016232 |
|
August 30, 2017 |
December 30, 2018 |
December 30, 2018 |
March 20, 2018 |
March 20, 2018 |
|
- Danish Headache Center
Glostrup, Denmark
|
|
| 88 |
NCT01942486 |
Recruiting |
Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine |
- Migraine Disorders
- Photophobia
|
- Device: Investigational Coating
|
Interventional
|
Not Applicable |
- University of Utah
- Primary Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HIT-6 Score
- Headache Frequency as Measured Using a Self-Reporting Daily Diary
|
50 |
All |
7 Years to 18 Years (Child, Adult) |
NCT01942486 |
IRB_00065178 |
|
January 2014 |
October 2017 |
October 2017 |
September 16, 2013 |
May 3, 2017 |
|
- Moran Eye Center
Salt Lake City, Utah, United States
|
|
| 89 |
NCT03418766 |
Not yet recruiting |
The Relationship Between Right-to-left Shunt and Brain White Matter Lesions in Patients With Migraine |
- White Matter Disease
- Right-to-left Shunt
- Migraine Disorders
|
|
Observational
|
|
- First Hospital of Jilin University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- contrast-enhanced transcranial Doppler (c-TCD)
|
1500 |
All |
18 Years to 50 Years (Adult) |
NCT03418766 |
CAMBRAIN |
CAMBRAIN |
July 2018 |
July 2019 |
December 2020 |
February 1, 2018 |
July 13, 2018 |
|
|
|
| 90 |
NCT01470352 |
Recruiting |
Multiparametric MRI Study of Endogenous Analgesia and Prediction the Efficacy of Migraine Pharmacological Prevention |
|
- Drug: Doluxetine
- Drug: Placebo
|
Interventional
|
Not Applicable |
- d_yarnitsky
- Rambam Health Care Campus
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Therapeutic response to the analgesic drugs
|
100 |
Female |
18 Years to 50 Years (Adult) |
NCT01470352 |
Migrain-0265-11CTIL |
|
December 2011 |
September 2017 |
September 2018 |
November 11, 2011 |
September 27, 2017 |
|
- Rambam health care campus
Haifa, Israel
|
|
| 91 |
NCT03568617 |
Not yet recruiting |
rTMS for the Prevention Treatment of CM: a Single Arm Study |
|
|
Interventional
|
Not Applicable |
- Peking Union Medical College Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 50% reduction in the Number of Days with Headache
- 50% reduction in the Number of Migraine Days
- 50% reduction in the Number of Moderate/Severe Headache Days
- (and 6 more...)
|
15 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03568617 |
rTMSCM-PUMCH |
|
June 30, 2018 |
December 31, 2021 |
June 30, 2022 |
June 25, 2018 |
June 25, 2018 |
|
|
|
| 92 |
NCT02549898 |
Recruiting |
Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI |
- Migraine Headache
- Migraine Without Aura
|
- Drug: Feraheme
- Drug: Cilostazol
- Other: USPIO-MRI
- Other: BBI-MRI
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change in USPIO uptake during attacks of unilateral migraine without aura compared to baseline
- Change in arterial wall thickness during attacks of unilateral migraine without aura compared to baseline
- Change in arterial circumference as a proxy measure for vascular inflammation during attacks of unilateral migraine without aura compared to baseline
- (and 3 more...)
|
42 |
Female |
18 Years to 50 Years (Adult) |
NCT02549898 |
H-15005669 |
|
August 2015 |
June 2018 |
June 2018 |
September 15, 2015 |
January 5, 2018 |
|
- Rigshospitalet Glostrup
Glostrup, Denmark
|
|
| 93 |
NCT03132233 |
Recruiting |
Energy for the Brain |
- Migraine
- Episodic Migraine
|
- Dietary Supplement: Beta-hydroxybutyrate calcium and magnesium salt
- Other: placebo powder
|
Interventional
|
Not Applicable |
- University Hospital, Basel, Switzerland
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of migraine days
- Number of headache days
- Acute migraine medication
- (and 3 more...)
|
45 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03132233 |
MigraKet |
MigraKet |
May 8, 2017 |
July 31, 2019 |
July 31, 2019 |
April 27, 2017 |
October 2, 2017 |
|
- University Children's Hospital (UKBB)
Basel, Basel-Stadt, Switzerland
|
|
| 94 |
NCT03472092 |
Not yet recruiting |
Distinct Mechanisms of Cognitive Behavioral Therapy Effects in Youth With Migraine |
- Headache, Migraine
- Migraine
- Migraine Disorders
- Headache
|
- Behavioral: Cognitive Behavioral Therapy (CBT)
- Drug: Placebo
- Drug: Amitriptyline
|
Interventional
|
Phase 2 |
- Children's Hospital Medical Center, Cincinnati
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Change in functional resonance imaging (fMRI)
- Change in pain modulation
|
240 |
All |
10 Years to 17 Years (Child) |
NCT03472092 |
CIN0101-CAP Imaging Study |
|
September 2018 |
December 2022 |
March 2023 |
March 21, 2018 |
March 27, 2018 |
|
- Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
|
| 95 |
NCT02447991 |
Recruiting |
Rizatriptan for Episodic Dizziness in Vestibular Migraine |
- Vestibular Migraine
- Migrainous Vertigo
|
- Drug: Rizatriptan
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Robert W. Baloh
- University of California, Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Proportion of treated vestibular migraine (VM) attacks in which subjects experience a reduction in severity rating
- Treatment Satisfaction at 48 hours
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02447991 |
IRB12-001549 |
|
December 2014 |
June 2019 |
June 2019 |
May 19, 2015 |
February 13, 2018 |
|
- University of California, Los Angeles
Los Angeles, California, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 96 |
NCT03269435 |
Recruiting |
Greater Occipital Nerve Block Versus Metoclopramide |
|
- Procedure: Greater occipital nerve block with bupivacaine
- Drug: Metoclopramide
|
Interventional
|
Phase 4 |
- Montefiore Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sustained headache relief
- Sustained headache freedom
- ED dwell time
- Improvement in 0-10 pain score
|
170 |
All |
18 Years and older (Adult, Older Adult) |
NCT03269435 |
2017-8249 |
|
November 1, 2017 |
August 2020 |
October 2020 |
August 31, 2017 |
December 12, 2017 |
|
- Montefiore Medical Center
Bronx, New York, United States
|
|
| 97 |
NCT00727974 |
Recruiting |
Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines |
|
|
Observational
|
|
- Medical College of Wisconsin
- Children's Hospital and Health System Foundation, Wisconsin
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Identify novel genes that contribute to the risk of CVS using genomewide association analysis approach.
- Perform genotype-phenotype correlations between genetic profiles and various phenotypes of CVS (e.g. menstrual, Sato, calendar-tied) and migraine headaches (e.g. with aura, without aura, hemiplegic migraine)
|
880 |
All |
up to 21 Years (Child, Adult) |
NCT00727974 |
08/24
GC 607 |
|
January 2008 |
December 2019 |
December 2019 |
August 5, 2008 |
March 23, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 98 |
NCT03539393 |
Available |
Expanded Access Program for Patients With Migraine |
|
|
Expanded Access
|
|
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
|
|
|
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03539393 |
TV48125-CNS-80005 |
|
|
|
|
May 28, 2018 |
May 28, 2018 |
|
|
|
| 99 |
NCT03177616 |
Recruiting |
Integrative Migraine Pain Alleviation Through Chiropractic Therapy |
- Migraine
- Migraine Disorders
- Migraine With Aura
- (and 2 more...)
|
- Other: Chiropractic Treatment
|
Interventional
|
Not Applicable |
- Harvard University Faculty of Medicine
- Brigham and Women's Hospital
- Palmer Center for Chiropractic Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in the number of migraine days per month
- Changes from baseline in the number of migraine days per month during post-intervention period
- Number of responders
- (and 10 more...)
|
60 |
Female |
20 Years to 55 Years (Adult) |
NCT03177616 |
2017P000087 |
IMPACT |
June 7, 2017 |
June 2019 |
June 2019 |
June 6, 2017 |
May 17, 2018 |
|
- The Osher Clinical Center for Integrative Medicine at Brigham and Women's Hospital
Boston, Massachusetts, United States
|
|
| 100 |
NCT03341689 |
Recruiting |
Psilocybin for the Treatment of Migraine Headache |
|
- Drug: High Dose Psilocybin
- Drug: Low Dose Psilocybin
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Acute change in pain intensity
- Acute change in nausea/vomiting
- Acute change in photophobia
- (and 18 more...)
|
24 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03341689 |
1607018057.A |
|
November 1, 2017 |
November 1, 2019 |
March 1, 2020 |
November 14, 2017 |
December 8, 2017 |
|
- VA Connecticut Healthcare System, West Haven Campus
West Haven, Connecticut, United States
|
|
Create an RSS feed from your search for:
Download the search results for: